Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Metadata
Title
Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*
Publication date
01-06-2002
Published in
Diabetologia / Issue 7/2002
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-002-0822-9

Other articles of this Issue 7/2002

Diabetologia 7/2002 Go to the issue

Letters

To: Chandie Shaw PK, Vanderbroucke JP, Tjandra YI et al. (2002) Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. Diabetologia 45: 337–341

Book Reviews

Embryonic Stem Cells: Methods and Protocols (2001) K. Turksen (ed) Humana Press, Totowa, pp 499 (ISBN 0-89603-881-5) hardcover, EUR 135.63

Article

Evaluation of apolipoprotein A-II as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance

Observations

Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients

Review

Hypoglycaemia unawareness and the brain

Article

Morpho-functional studies of the blood-brain barrier in streptozotocin-induced diabetic rats

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits